<DOC>
	<DOCNO>NCT00982553</DOCNO>
	<brief_summary>The purpose study look level new anti-HIV drug call raltegravir exist anti-hepatitis C drug call ribavirin see affect blood level give separately together . This phase I , open-label , prospective , three phase , pharmacokinetic study .</brief_summary>
	<brief_title>The Raltegravir Ribavirin Pharmacokinetics ( PK ) Study</brief_title>
	<detailed_description>Phase I ( study day 1 - 14 ) : - 14 healthy volunteer document negative HIV-1 antibody test screening procedure enrol . - On day 1 , fast subject administer ribavirin 800 mg without food ( witnessed dosing ) . This follow 12 hour detail pharmacokinetic assessment ; blood sample drawn 0 ( pre-dose ) , 0.5 , 1 , 2 , 3 , 4 , 6 , 8 12 hour . - This follow wash-out period . - As steady state pharmacokinetics ribavirin reach several week , single dose pharmacokinetics assess study Phase II ( study day 15 - 19 ) : - On day 15 , subject commence raltegravir 400 mg twice daily . Subjects attend safety visit witness dose phase . - Day 19 - 4 day dose steady state pharmacokinetics reach , subject attend 12 hour detail pharmacokinetic visit follow witnessed administration raltegravir 400 mg without food , blood sample drawn 0 ( pre-dose ) , 0.5 , 1 , 2 , 3 , 4 , 6 , 8 12 hour post dose assessment raltegravir plasma exposure . Phase III ( study day 20 ) : â€¢ Subjects administer raltegravir 400 mg ribavirin 800 mg without food . This follow 12 hour detail pharmacokinetic assessment blood sample drawn 0 ( pre-dose ) , 0.5 , 1 , 2 , 3 , 4 , 6 , 8 , 12 hour .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>The ability understand sign write informed consent form , prior participation screening procedure must willing comply study requirement . Male nonpregnant , nonlactating female . Between 18 60 year , inclusive . Subjects good health upon medical history , physical exam , laboratory test body mass index 32 . Female subject heterosexually active childbearing potential ( i.e. , surgically sterile least two year post menopausal ) must practice contraception follow screen completion study include 180 day follow last dose study drug : barrier contraceptive ( condom , diaphragm spermicide ) oral combine contraceptive pill , implant injectable hormonal contraceptive PLUS barrier contraceptive Intrauterine device ( IUD ) intrauterine system ( IUS ) PLUS barrier contraceptive ( partner vasectomize least six month ) . Female subject childbearing potential must negative urine pregnancy test . Male subject heterosexually active must use two form barrier contraception ( e.g. , condom spermicide ) heterosexual intercourse , screen completion study include 180 day follow last dose study drug . Have serologic evidence HIV infection . Have serologic evidence active hepatitis B virus infection evidence negative hepatitis B surface antigen serologic evidence hepatitis C virus infection antibody test . Have screen laboratory result ( haematology , chemistry ) fall within normal range central laboratory 's reference range unless result determine Investigator clinical significance . Any serious active medical psychiatric illness , opinion Investigator , would interfere subject treatment , assessment , compliance protocol . This would include active clinically significant renal , cardiac , hepatic , pulmonary , vascular , metabolic ( thyroid disorder , adrenal disease ) , immunodeficiency disorder , active infection , malignancy . Have body mass index ( BMI ) great 32 Previous participation investigational trial involve administration investigational compound within 1 month prior study screen . Clinically relevant alcohol drug use ( positive screen drug screen ) history alcohol drug use consider Investigator sufficient hinder compliance treatment , followup procedure evaluation adverse event . Smoking permit , tobacco intake remain consistent throughout study . Any medication take listed Prior Concomitant Medication section include overthecounter medication herbal product within 21 day commence study drug dose exception vitamin and/or paracetamol and/or hormonal contraceptive include combined oral contraceptive pill , DepoProvera Mirena intrauterine system . When concomitant medication necessary , review Investigator contraindicate , may continue dose frequency study period . History drug sensitivity drug allergy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>